BioSpace News Archive

Leading GPO Accepts MolecuLight i:X Point-of-Care Device for Detection of Bacteria and Digital Wound Measurement for its National Membership

Results show a pre-treatment with a micro dose (150 µg) of Gvoke RTU Micro significantly prevented Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a real-world setting with or without adjustment to insulin

Appili Therapeutics Inc. is pleased to announce that its common shares began trading on the OTCQX Best Market®.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to begin a Phase 1/2a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy.

Parkway Clinical Laboratories Inc. (PCL), today announced it has launched COVID-19 Immune Response Serum Immunoglobin IGG Antibody test available directly to consumers.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that effective today it has appointed Andrei Floroiu as Chief Executive Officer.

Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute

MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia

Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that the company has received favorable coverage decisions for Prolaris® from three new commercial health plans including one of the top five national providers of health insurance.